15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 6 firms covering Immuneering Corp, 6 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets range widely, $11.00 to $30.00 (about 2.7x), a sign of real disagreement on valuation. The average target of $18.80 sits 344% above the current $4.24. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.31 next quarter toward $-1.29 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 ratings
Strong Buy
Strong Buy00%
Buy6100%
Hold00%
Sell00%
Strong Sell00%
Based on 6 analysts giving stock ratings to Immuneering Corp.
As of Jul, 6 of 6 firms rate IMRX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
IMRX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.31
Range $-0.37 – $-0.25 · 7 analysts · -20% YoY
Next period, 7 analysts expect Immuneering Corp to earn $-0.31 a share (range $-0.37 – $-0.25), versus $-0.38 a year earlier. Full-year consensus is $-1.11, growing to $-1.29 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 7 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $19.5M next year.
Top analysts covering Immuneering Corp
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on IMRX.
#1
Ami Fadia
Needham · Rank #90
Buy
$18.00+325.0% to target
Overall win rate
46%
+ Follow
#2
Geulah Livshits
Chardan Capital · Rank #100
Buy
$20.00+372.3% to target
Overall win rate
44%
+ Follow
#3
Andrew Berens
Leerink Partners · Rank #167
Buy
$15.00+254.2% to target
Overall win rate
50%
+ Follow
#4
Li Watsek
Cantor Fitzgerald · Rank #218
Buy
No targeton IMRX
Overall win rate
38%
+ Follow
#5
Jay Olson
Oppenheimer · Rank #302
Buy
$30.00+608.4% to target
Overall win rate
32%
+ Follow
IMRX stock forecast FAQ
What is IMRX's average 12-month price target?+
The 5 analysts with a live target average $18.80 for Immuneering Corp over the next 12 months, ranging from a $30.00 high to a $11.00 low.
Is IMRX stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 6 analyst ratings, 6 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for IMRX?+
The Street-high target is $30.00 (Oppenheimer), and the Street-low is $11.00 (HC Wainwright & Co.). The average of all 5 active targets is $18.80.
How many Wall Street analysts cover IMRX?+
6 analysts have an active rating on Immuneering Corp, and 5 firms carry a live 12-month price target.
Who is the most accurate analyst covering IMRX?+
Among analysts who currently cover IMRX, Ami Fadia of Needham has the strongest overall Quantellect track record (Rank #90). Their current call is Buy with a $18.00 target.
What is Immuneering Corp's projected EPS for next quarter?+
The consensus estimate is $-0.31 per share (range $-0.37 – $-0.25) across 7 analysts. Full-year EPS is projected at $-1.11, rising to $-1.29 the following year.
How much revenue is Immuneering Corp expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $19.5M next year.
Have analysts been upgrading or downgrading IMRX lately?+
As of Jul, 6 of 6 firms rate IMRX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their IMRX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
